Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,574JPY
30 Sep 2016
Change (% chg)

¥-26 (-1.66%)
Prev Close
¥1,600
Open
¥1,582
Day's High
¥1,585
Day's Low
¥1,564
Volume
6,762,100
Avg. Vol
7,988,462
52-wk High
¥1,804
52-wk Low
¥1,358

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥3,446,117.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 2.00

Financials

  4503.T Industry Sector
P/E (TTM): 15.92 36.94 36.87
EPS (TTM): 100.51 -- --
ROI: 16.06 14.36 13.86
ROE: 17.09 15.19 14.81

BRIEF-Cytokinetics announces early termination of Hart-Scott-Rodino waiting period

* Announces Early Termination Of Hart-Scott-Rodino waiting period for expanded collaboration with astellas

29 Sep 2016

BRIEF-Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan

* Says the co received a marketing approval of Kiklin Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan

28 Sep 2016

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

19 Sep 2016

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

19 Sep 2016

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook - R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" - R&I

08 Sep 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

22 Aug 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion (11 billion pounds) in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

22 Aug 2016

UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal

Aug 22 Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

22 Aug 2016

BRIEF-Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan

* Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder

09 Aug 2016

BRIEF-Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

* Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

08 Aug 2016

Earnings vs. Estimates